Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating risk of late versus early relapse for patients with diffuse large B-cell lymphoma

Posted by on Sep 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the risk of relapse 5 years or more after treatment for patients with diffuse large B-cell lymphoma (DBLCL). This study concluded that the outcomes of patients with a late relapse were better than those in patients who relapsed early after treatment. Some background DLBCL is one of the most common types of...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating blinatumomab for patients with recurrent or non-responsive non-Hodgkin’s lymphoma

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term safety and effectiveness of blinatumomab (Blincyto) for non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The authors concluded that blinatumomab showed promising effectiveness for these patients, with minimal side effects. Some background Chemoimmunotherapy...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Fertility options for female patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...

Read More

Which patients with mantle cell lymphoma may benefit from stem cell therapy?

Posted by on Aug 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed which patients with mantle cell lymphoma benefitted most from a stem cell transplant. Some background Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin's lymphoma. It can be challenging to treat. There is no single standard treatment for patients with MCL. However, for young and fit patients, intensive...

Read More

Can immune profiling help predict outcomes for patients with NHL after a stem cell transplant?

Posted by on Aug 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Posted by on Aug 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More

Looking for patients with non-Hodgkin lymphoma to test new treatment using patient’s own immune cells

Posted by on Aug 22, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial is examining the effectiveness of CTX110, a treatment that modifies a patient’s own immune cells to treat relapsed or unresponsive non-Hodgkin lymphoma (NHL). The main outcome of this study is to see the number of patients that respond to treatment and side effects experienced. This study is recruiting in...

Read More

Evaluating different doxorubicin doses for patients with diffuse large B-cell lymphoma

Posted by on Aug 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Evaluating the impact of high calcium levels on patient outcomes in diffuse large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the impact of high levels of calcium in the blood on the outcomes of patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that this condition is common patients with DLBCL and can lead to poorer outcomes. Some background About 25% of patients with cancer develop hypercalcemia (HC). This means...

Read More